Case report

A case report of retroperitoneal Ewing sarcoma requiring adrenalectomy

Rema AlRashed a,⁎, Hussam AlHarbi a, Faraouq Abdulfattah a, Ibrahim Alhasan b, Feras Alsannaa c

a General surgery, resident, Prince Sultan Military Medical City, Riyadh Saudi Arabia
b Consultant General Surgery and Hepatobiliary Surgery, Prince Sultan Military Medical City, Riyadh Saudi Arabia
c Consultant General Surgery/Acute Care and Trauma Surgeon, Prince Sultan Military Medical City, Riyadh Saudi Arabia

ARTICLE INFO

Keywords:
Ewing sarcoma
Surgical oncology
Extra-skeletal Ewing sarcoma
Adrenalectomy

ABSTRACT

Introduction and importance: Ewing’s sarcoma is a rare entity of malignant in both skeletal and extra-skeletal sites. There are few patients reported as Extra-Skeletal Sarcoma, and fewer reported cases for Extraskeletal Ewing sarcoma involving the retroperitoneal region. Reporting such a rare entity will add to literature in helping the diagnosis and management of such cases.

Case presentation: We present a case of 26 year old previously healthy female complaining of a vague abdominal pain and discovered to have retroperitoneal Ewing sarcoma adherent to left adrenal gland.

Clinical discussion: She was managed with a combination of neoadjuvant chemotherapy and resection through exploratory laparotomy.

Conclusion: In short, Ewing sarcoma should be considered in the differential diagnosis for young patient who is presenting with a retroperitoneal mass.

1. Introduction

Soft tissue sarcomas are rare adult malignancies that can be classified into over 100 histopathological subtypes. Ewing sarcoma (ES) is a subtype usually observed as “small round blue cells” on microscopic examination [1]. ES is usually characterized by the t(11;22)(q24;q12) translocation, which generates oncogenic chimeric fusion transcripts between the EWSR1 and FLI1 genes [2].

ES is Ewing sarcoma is further classified according to its site to: Skeletal Ewing Sarcoma (SES), and Extraskeletal Ewing Sarcoma (EES). ES has an incidence of 1 case per million per year with a lower incidence for EES [1].

ES can be further classified according to site into skeletal Ewing sarcoma (SES) and extraskeletal (extraosseous) Ewing sarcoma (EES). ES is already a rare tumor, with an incidence of 1 case per million per year, but the incidence of EES is even lower which account 6% to 47% of all Ewing sarcoma [1,3]. EES most commonly occurs in the trunk and extremities however it’s even less in the retroperitoneum only few cases have been reported in the studies [4,5]. When retroperitoneal ES does occur, its location makes it both a diagnostic and management challenge. Here we report a very rare retroperitoneal ES and its subsequent management.

2. Case report

This case report was done in line with the SCARE criteria, and written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

A previously healthy 26-year-old woman presented to clinic with a four-month history of progressive left-sided abdominal pain with no specific relieving or aggravating factors. The pain radiated to the back and left loin and was associated with generalized fatigue. There was no history of nausea, vomiting, change in bowel or urine habits, fever, loss of weight or appetite, nor night sweats. There was no past medical or surgical history of note, and she had two children.

On physical examination, the patient looked well, and her vital signs were normal. All laboratory tests, including a pregnancy test, glucose, and tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen (CA19-9), cancer antigen (CA125), and alpha fetoprotein (AFP)] were normal.

⁎ Corresponding author.
E-mail addresses: dr.reemaf@gmail.com (R. AlRashed), feras.alsannaa@hotmail.com (F. Alsannaa).

https://doi.org/10.1016/j.ijscr.2022.106966
Received 6 December 2021; Received in revised form 24 March 2022; Accepted 25 March 2022
Available online 11 April 2022

© 2022 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Computed tomography (CT) of the abdomen and pelvis with contrast revealed a complex but well-defined 17 × 12 × 10 cm bilobed retroperitoneal mass with cystic components running inferiorly in the peritoneum, displacing the pancreatic body and tail anteriorly and the upper part of left kidney posteriorly, but without invasion. The inferior part of the mass was inseparable from the third part of duodenum, proximal jejenum, and left adrenal gland. There was a small amount of free pelvic fluid and no evidence of regional or distant lymphovascular invasion in the abdominal CT (Fig. 1A).

The differential diagnosis included myxoid soft tissue sarcoma, adrenal cortical carcinoma, or, less likely, gastrointestinal stromal tumor (GIST). The abdominal CT showed an incidental finding of a septate or arcuate uterus without ovarian anomalies, for which abdominal and pelvic MRI was recommended for further evaluation. The subsequent abdominal and pelvic MRI was consistent with the CT findings: the mass measured 18.7 × 10.7 × 11.1 cm and showed high signal intensity in T2-weighted images and moderately intense signal in T1 images suggesting a myxoid component with hemorrhagic foci, central necrosis, and peripheral enhancement. Again, the mass was inseparable from the third and fourth parts of duodenum and proximal jejenum. Furthermore, the mass encased the inferior mesenteric vein with possible encasement of the inferior mesenteric artery (Fig. 1B). The mass abutted the left kidney and left renal vein posteriorly and pancreatic body and tail anteriorly without definite invasion. The liver showed mild hepatic steatosis without focal lesions and no intra or extrahepatic duct dilatation, the uterus was unremarkable, and there was no significant abdominal or pelvic lymph node enlargement. A CT chest with contrast was unre

The patient underwent an ultrasound-guided but inconclusive True-Cut needle biopsy, but a repeat biopsy showed round cell sarcoma. Fluorescence in situ hybridization (FISH) for the Ewing sarcoma breakpoint region 1 (EWSR1) gene rearrangement was positive.

The case was discussed at the multidisciplinary meeting, and the decision was made to start her on neoadjuvant chemotherapy: 6 cycles of vincristine, doxorubicin, and cyclophosphamide (VDC) and ifosfamide and etoposide (IE). She was started on leuprolide for ovarian inhibition. FISH for the Ewing sarcoma breakpoint region 1 (EWSR1) was positive and the abdomen and skin were closed in the usual fashion. Hemostasis was maintained and the abdomen and skin were closed in the usual fashion.

Post-operatively, the patient recovered well and was discharged home on day 5. Final histopathological analysis showedextensive necrosis, fibrosis, and hemorrhage consistent with a chemotherapy affect and focal residual round blue cell tumor consistent with Ewing sarcoma. The margins were free of tumor, so the resection was considered complete. The tissue was again EWSR1 rearrangement positive by FISH. The left adrenal specimen showed evidence of hemorrhage and necrosis with no evidence of malignancy. The para-aortic lymph node was negative for malignancy. Currently, the patient is completing her adjuvant chemotherapy without radiotherapy for residual disease to consolidate her treatment.

3. Discussion

Ewing sarcoma (ES) is a rare malignant tumor arising from mesenchymal cells. Its classical morphological appearance is of small round blue cells, and it can develop in bone or soft tissue [1]. ES is more common in children and it is rare in adults, with a peak incidence between 10 and 30 years of age [1]. It was previously believed that ES only occurs in the skeletal system, until Tefft et al. reported the first case of EES in Boston in 1969 [7]. Despite the fact that EES and skeletal ES harbor a similar genetic translocation, EES is reported to have a higher rate of distant metastasis especially to lungs and bones which mandates thorough screening of the whole body prior to definitive management. Different imaging modalities including CT, MRI, and PET are used to localize the disease and to assess for metastasis; however, the definitive diagnosis of ES is by tissue biopsy [10].

Retroperitoneal Ewing Sarcoma is a less frequent entity of the disease and more diagnostically challenging. As it’s presented with nonspecific abdominal pain. EES often spares the regional lymph nodes but has a higher rate of distant metastasis, especially to lungs and bones which mandate thorough screening of the whole body before management. Different imaging modalities CT, MRI, PET scan are used for localizing the disease and assessing for metastasis however the definitive diagnosis for Ewing Sarcoma is by core needle or true-cut biopsy [8].

Histological examination usually involves immunohistological assessment and FISH for the 22q12 (EWSR1) rearrangement, which is more specific for ES [11].

The management of retroperitoneal ES, including EES, consists of systemic chemotherapy and local control through surgical resection and/or radiotherapy. VDC chemotherapy in combination with
Ifosfamide and etoposide has been associated with a better five-year event-free survival overall survival in patients with non-metastatic ES [12]. Indeed, in our case, the patient responded well to this regimen in terms of immediate response, the reduction in size and local invasion allowing for local control with surgery alone and complete resection.

We elected to perform partial adrenalectomy, since the adrenal gland was adherent to the mass. Our decision to omit radiotherapy was based on existing data showing no difference in local recurrence after surgery and chemotherapy compared with surgery, chemotherapy, and radiotherapy [13]. Moreover, Cash et al. reported that radiotherapy was more often associated with positive margins when used for EES compared with SES [8].

In this case the response to neoadjuvant VDC, with ifosfamide and etoposide resulted in a good response in term of reduction the size and local invasion and allowed for local control with surgery alone obtaining clear margins.

She is currently undergoing the consolidation phase of treatment.

We conducted to do partial adrenalectomy to achieve oncological resection as it was adherence to the mass. Our decision for local control was to go for surgery without radiation therapy which consistent with the finding that surgery and chemotherapy did not affect the rate of local recurrence when compared with surgery, chemotherapy and radiation. [13] Moreover, Cash T et al., reported that using radiation therapy was associated with positive margins when used in EES more frequently than when it’s used in SES. [7]

4. Conclusion
Retroperitoneal Ewing sarcoma is very rare type of sarcoma. We report a case of young female lady with retroperitoneal Ewing sarcoma. Although it’s a rare disease, it should be considered in the differential diagnosis for young patient presenting with a retroperitoneal mass.

Provenance and peer review
Not commissioned, externally peer-reviewed.

Sources of funding
No funding.

Ethical approval
NA

Consent
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Author contributions
Dr. Rema AlRashed writing manuscript and primary author
Dr. Hussam alharbi and dr. Farouq fattah: writing manuscript.
Dr. Ibrahim Alhasan: Literature review.
Dr. Feras Alsanna: Primary consultant, and final modifications.

Research registration (for case reports detailing a new surgical technique or new equipment/technology)
NA.

Guarantor
NA

Declaration of competing interest
No conflict of interest.

References
[1] M.U. Jawad, M.C. Cheung, E.S. Min, M.M. Schneiderbaser, L.G. Koniaris, S. P. Scully, Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005, Cancer: Interdisciplinary International Journal of the American Cancer Society 115 (15) (2009 Aug 1) 3526–3536.
[2] S.A. Burchill, Ewing’s sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities, J. Clin. Pathol. 56 (2) (2003 Feb) 96–102, https://doi.org/10.1136/jcp.56.2.96. PMID: 12560386; PMCID: PMC1769883.
[3] B. Biswas, N.K. Shukla, S.V. Deo, S. Agarwala, D.N. Sharma, S. Vishnubhatla, S. Bakhshi, Evaluation of outcome and prognostic factors in extraosseous Ewing sarcoma, Pediatr. Blood Cancer 61 (11) (2014 Nov) 1925–1931, https://doi.org/10.1002/pbc.25095. Epub 2014 Aug 17 PMID: 25132242.
[4] F. Reis, E. Macedo, M.C. Franca, E.I. Amstalden, S. Appenzeller, Retroperitoneal Ewing’s sarcoma/embryonal tumor: a rare differential diagnosis of back pain, Radiol. Bras. 50 (2017 Nov) 409–410.
[5] J. Spacek, K. Kopeckova, J. Kostina, J. Pacovsky, J. Petera, L. Krhal, M. Mrhalova, P. Dvorak, M. Brofak, Primary retroperitoneal ewings sarcoma, Rozhl. Chir. 98 (3) (2019 Jan 1) 121–124.
[6] M. Tefft, G.F. Vawter, A. Mitus, Paravertebral, “round cell” tumors in children, Radiology 92 (7) (1969 Jun) 1501–1509.
[7] T. Cash, E. McIlvaine, M.D. Krailo, S.L. Lessnick, E.R. Lawlor, N. Laack, J. Sorger, N. Martina, H.E. Grier, L. Granovetter, R.B. Womer, Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing
sarcoma: a report from the Children’s oncology group, Pediatr. Blood Cancer 63 (10) (2016 Oct) 1771–1779.

[9] J. Xiong, K. Zhu, J. Mao, J. Cai, M. He, L. Li, J. Wang, L. Wang, Ewing-like sarcoma/undifferentiated round cell sarcoma in an infant with APC and MSH6 variation: a case report, Medicine 98 (45) (2019 Nov).

[10] O. Javery, K. Krajewski, K. O’Regan, B. Kis, A. Giardino, J. Jagannathan, N. H. Ramaiya, A to Z of extraskeletal Ewing sarcoma family of tumors in adults: imaging features of primary disease, metastatic patterns, and treatment responses, AJR Am. J. Roentgenol. (2011).

[11] J.H. Choi, J.Y. Ro, Retroperitoneal sarcoma: an update on the diagnostic pathology approach, Diagnostics 10 (9) (2020 Sep) 642.

[12] H.E. Grier, M.D. Krailo, N.J. Tarbell, M.P. Link, C.J. Fryer, D.J. Pritchard, M. C. Gebhardt, P.S. Dickman, E.J. Perlman, P.A. Meyers, S.S. Donaldson, Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone, N. Engl. J. Med. 348 (8) (2003 Feb 20) 694–701.

[13] D. Boyce-Fappiano, B.A. Guadagnolo, R. Ratan, W.L. Wang, M.J. Wagner, S. Patel, J.A. Livingston, P.P. Lin, K. Diao, D. Mitra, A. Farooqi, Evaluating the soft tissue sarcoma paradigm for the local management of extraskeletal Ewing sarcoma, Oncologist 26 (3) (2021 Mar) 250–260.